The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients not candidates for optimal primary surgery: Safety and effectivenes.
Vanessa Costa Miranda
No relevant relationships to disclose
Angelo Bezerra de Sousa Fede
No relevant relationships to disclose
Carlos Henrique Dos Anjos
No relevant relationships to disclose
Juliana Ribeiro da Silva
No relevant relationships to disclose
Fernando Barbosa Sanchez
No relevant relationships to disclose
Lyvia Rodrigues da Silva Bessa
No relevant relationships to disclose
Jesus Paula Carvalho
No relevant relationships to disclose
Dr Elias Abdo Filho
No relevant relationships to disclose
Daniela Freitas
No relevant relationships to disclose
Laryssa Almeida Borges de Barros
No relevant relationships to disclose
Samantha Cabral Severino da Silva
No relevant relationships to disclose
Maria Del Pilar Estevez-Diz
No relevant relationships to disclose